Gerry Prud'homme works closely with medical device companies to get their products approved by the FDA. He has more than 20 years of experience helping companies with FDA regulatory strategy and medical device submissions, including investigational device exemptions (IDEs), premarket approvals (PMAs), 510(k)s, and de novo applications. He is one of the few FDA lawyers in the country who is also a biostatistician with expansive experience in clinical studies.

With a technical background, Gerry also advises medical device clients on scientific requirements to get their products approved by the FDA. Having 30 years of experience in clinical trials, he routinely helps clients design and analyze all types of medical device clinical studies — from first-in-human to feasibility, pilot, pivotal, and post-approval studies. He is widely recognized for his experience in this area. Gerry often lectures new FDA employees on IDEs and PMAs.

Understanding the critical nature of FDA panel meetings to clients, Gerry works hand-in-glove with medical device and pharmaceutical companies, together with their expert clinicians and statisticians in preparing for advisory committee meetings. Often coordinating the entire process, he brings a wealth of knowledge and experience to clients preparing for panel meetings and is nationally well-regarded for his capabilities and depth of experience.

Gerry also regularly works closely with companies on issues relating to bioresearch monitoring, institutional review boards (IRBs), informed consent, advertising and promotion of medical devices, and regulatory due diligence reviews, as well as a variety of other FDA matters.

Gerry has authored a number of articles and book chapters on topics relating to regulation of medical devices, as well as scientific articles relating to medical devices, drugs, and clinical studies.

We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click accept.